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Micro CTOsteoclast differentiation is associated with both normal bone homeostasis and pathological bone diseases such
as osteoporosis. Several transcription factors can regulate osteoclast differentiation, including c-fos and Nfatc1.
Using genome-wide DNase-seq analysis, we found a novel transcription factor, SREBP2, that participates in oste-
oclast differentiation in vitro. Here, we asked whether SREBP2 actually plays a role in controlling bone metabo-
lism in vivo. To answer this question, RAW264 cells, primary cultured osteoclasts and the mouse RANKL-
induced bone loss model were treated with fatostatin, a small molecule inhibitor speciﬁc for the activation of
SREBP.When cells were treated with fatostatin, osteoclast differentiation was impaired. Similar results were ob-
tained following treatment with siRNA for Srebf2, the gene coding for SREBP2. In vivo, μCT analyses showed that
fatostatin treatment preserved bone mass and structure in the proximal tibial trabecular bone in the mouse
RANKL-induced bone loss model. In addition, bone histomorphometric analysis revealed that the protection of
bonemass by fatostatinmight have been achieved by suppression of RANKL-mediated osteoclast differentiation.
These results indicated that the novel transcription factor SREBP2 physiologically functions in osteoclast differen-
tiation in vivo and might be a possible therapeutic target for bone diseases.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Bone tissue is continuously remodeled by osteoclastic bone resorp-
tion and osteoblastic bone formation [1]. Together, osteoclasts and
osteoblasts maintain bone homeostasis [2]. Abnormal osteoclast differ-
entiation or activity causes an imbalance in bone remodeling and results
in skeletal diseases, including osteoporosis and osteopetrosis [3]. Osteo-
clast differentiation consists of multiple steps. Preosteoclasts differenti-
ate from monocyte/macrophage lineage cells after stimulation by
macrophage colony-stimulating factor (M-CSF) and receptor activator
of NF-κB ligand (RANKL). Subsequently, preosteoclasts fuse and differ-
entiate into mature multinucleated osteoclasts [4]. This differentiation
process must be tightly regulated by a complex network of various
osteoclastogenic transcription factors, such as c-Fos [5], and nuclear fac-
tor of activated T cells calcineurin-dependent 1 (Nfatc1) [6]. These tran-
scription factors successively and cooperatively induce the expression
of osteoclastogenic genes including tartrate-resistant acid phosphatase
(Acp5) [7] and Cathepsin K (CtsK) [8]. Therefore, elucidation of theding protein; RANKL, receptor
hage colony-stimulating factor;
K; LdlR, low-density lipoprotein
1-0295, Japan.transcriptional mechanism underlying osteoclast differentiation is es-
sential for understanding both the physiology of bone homeostasis
and the pathology of skeletal disorders.
To unravel the transcriptional mechanism underlying osteoclast dif-
ferentiation, we previously performed DNase-seq [9], which is a power-
ful tool to identify DNase hypersensitive sites (DHSs) and transcription
factors binding to the DHSs [10].We used a RANKL-dependent differen-
tiation model with the murine macrophage cell line, RAW264. In the
study, we succeeded in identifying osteoclast-speciﬁc DHSs. This
genome-wide information allowed us to identify not only well-known
transcription factors but also novel transcription factors in osteoclast
differentiation, such as Atf1, Zscan10, Nrf1 and Srebf2. These novel tran-
scription factors positively regulate osteoclast differentiation in vitro.
However, their precise physiological and pathological functions in
bone metabolism are still unknown. To investigate the functions of
these transcription factors, we have initially focused on SREBP2
(encoded by Srebf2). SREBP2 is a master regulator of cholesterol metab-
olism [11], and several studies found a strong relationship between os-
teoclast differentiation/function and cholesterol homeostasis [12–14].
Sterol regulatory element binding protein 2 (SREBP2) is best known
as a transcription factor regulating cholesterol homeostasis through
transcriptional activation of its target genes, including LDL receptor,
HMG-CoA synthase and HMG-CoA reductase [15,16]. SREBP2 has a
basic-helix-loop-helix leucine zipper (bHLH-Zip) domain at the N-
terminal side and its regulatory domain is at the C-terminal side [17].
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plasmic reticulum (ER) membrane where it forms a complex with
SREBP cleavage activating protein (SCAP) [18]. When intracellular cho-
lesterol levels are reduced, SREBP2 is proteolytically cleaved by S1P and
S2P proteases at the membrane to release the N-terminal amino acids
containing the bHLH-Zip domain, generating the mature form of
SREBP2 [19,20]. Mature SREBP2 translocates into the nucleus and
binds to sterol regulatory elements (SREs) within the promoter region
of its target genes to activate their transcription [21]. SREBP2 is ubiqui-
tously expressed, and the physiological functions of SREBP2 in choles-
terol metabolism have been explored in several tissues, including
hepatocytes, adipocytes, endothelial cells, macrophages and male
germ cells [22–25].
SREBP2 functions in vivo have been investigated by the utilization of
tissue-speciﬁc SREBP2-overexpressing transgenic (SREBP2-Tg) mice.
PEPCK promoter-driven SREBP2-Tg mice conditionally overexpress
SREBP2 in the liver and adipose tissue, and analysis of the Tg mice re-
vealed that SREBP2 preferentially activates cholesterol biosynthesis
rather than fatty acid synthesis in the liver and adipose tissue [22]. Pan-
creatic β-cell speciﬁc SREBP2-Tg mice under control of the rat insulin
promoter exhibited severe diabetes due to loss ofβ-cellmasswith accu-
mulation of cholesterol [26]. Intestinal SREBP2-Tg mice showed an in-
crease of cholesterol levels not only in the jejunum but also in the
serum [27]. Although SREBP2-Tg mice revealed physiological roles of
SREBP2, phenotypes of Tg mice do not always reﬂect physiological con-
ditions. Therefore, loss-of-function studies in vivo are required to inves-
tigate the true physiological functions of SREBP2. However, systemic
SREBP2 knockout mice show complete embryonic lethality at an early
stage of development [28,29], and conditional SREBP2 knockout mice
have not yet been reported. Recently, to analyze the loss of SREBP
(SREBP1a, 1c and 2) functions in vivo, a small molecule compound
that inhibits activation of SREBPs has been discovered. The inhibitor,
named fatostatin, blocks SREBP translocation from the ER to the Golgi
apparatus through binding to SCAP [30]. Long-term fatostatin treatment
reduced body weight, blood glucose levels and adiposity in ob/obmice
through its inhibition of SREBP activation. We therefore postulated
that the physiological functions of SREBP2 in osteoclasts might be eluci-
dated by inhibition of SREBP2 activation by fatostatin treatment. To test
this hypothesis, we investigated whether fatostatin treatment affected
SREBP2 activation in osteoclasts, osteoclast differentiation in vitro and
bone metabolism in vivo using a RANKL-induced bone loss model.
2. Materials and methods
2.1. Animals and cell lines
C57BL/6J female mice were purchased from CLEA Japan. Animal ex-
periments were approved by the Animal Experiment Committee of
Ehime University and were performed in accordance with the Guide-
lines of Animal Experiments of Ehime University. Murine RAW264
cells and MC3T3-E1 cells were obtained from the RIKEN cell bank
(RIKEN BRC, Japan). RAW264 cells were cultured in osteoclast culture
medium (MinimumEssentialMedia Alpha (MEMα) (Life Technologies,
USA) supplemented with 10% Cellect fetal bovine serum (FBS) (MP Bio-
medicals, USA), 1% antibiotic–antimycotic solution (Life Technologies)
and 1% MEM non-essential amino acids (Life Technologies)). MC3T3-
E1 cells were maintained in osteoblast culture medium (MEM α
supplemented with 10% FBS (Nichirei Biosciences, Inc., Japan), and 1%
antibiotic–antimycotic solution).
2.2. Primary osteoclast differentiation
Primary osteoclast differentiation was performed as previously de-
scribed [9]. Brieﬂy, murine bone marrow macrophages (BMMs) were
isolated from the humeri, femora and tibiae of C57BL6 female mice at
8 weeks of age and were maintained in osteoclast culture mediumwith 10 ng/mL M-CSF for 2 days. For osteoclast differentiation, BMMs
were plated in 6-well plates at a density of 1 × 105 cells/well and
were treated with 234 ng/mL GST-RANKL (Oriental Yeast Co., Ltd.,
Japan) and 10 ng/mLM-CSF (R&D Systems, USA) for 3 days. At each in-
dicated time point, cells were collected for RNA extraction.
2.3. siRNA transfection of RAW264 cells and osteoclast differentiation
siRNA transfection and osteoclast differentiation assay were per-
formed as previously described [9]. Brieﬂy, AllStar negative control
siRNA (Qiagen, USA) and Srebf2 siRNA (Sigma-Aldrich, USA) were
used at a ﬁnal concentration of 150 nM. Each siRNA was transfected
into RAW264 cells (1 × 105 cells) using the Neon transfection system
(Invitrogen). Following transfection (36 h) total RNAs were extracted
from transfected cells and subjected to real-time RT-PCR. For osteoclast
differentiation, RAW264 cells were seeded in 24-well plates at a density
of 1 × 104 cells/well and were treated with 117 ng/mL GST-RANKL for
3 days. Differentiated cells were ﬁxed with 4% paraformaldehyde
(PFA) for 15 min. After washing with phosphate-buffered saline (PBS)
twice, the ﬁxed cells were permeabilizedwith an equal volumemixture
of acetone and ethanol for 30 s and then treated with TRAP staining so-
lution (0.01% naphthol AS-MX phosphate (Sigma-Aldrich) and 0.06%
Fast Red Violet LB Salt (Sigma-Aldrich) in 50mM sodium tartrate dehy-
drate and 45 mM sodium acetate (pH 5.0)). TRAP-positive multinucle-
ated cells (N3 nuclei/cell) were counted as mature osteoclasts.
2.4. Cell viability assay
Cell viability assays were performed by using an MTT (3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide) Cell Count
Kit (Nacalai Tesque, Japan) according to the manufacturer's protocol.
RAW264 cells and BMMS were seeded in 96-well plates at a density
of 1.25 × 104 cells/well. The cells were treated with vehicle (EtOH)
or fatostatin (5, 10, 15, 20 μM) for 48 h. Then, 10 μL of MTT solution
(5 mg/mL) was added in each well, and the cells were incubated for
3 h in the CO2 incubator. After incubation, the media were aspirated
and cells were dissolved by addition of 100 μL of solubilization solu-
tion. Then, the absorbance at 570 nm (reference: 650 nm) was mea-
sured with a FlexStation 3 (Molecular Devices, Japan).
2.5. Osteoblast differentiation
In vitro osteoblast differentiationwas performed by usingMC3T3-E1
cells. MC3T3-E1 cells were plated in 6-well plates and were cultured
with osteoblast culture medium until they became fully conﬂuent.
Then, medium was replaced with osteoblast differentiation medium
(osteoblast culture medium supplemented with 100 ng/mL BMP-2
(R&D, USA), 50 μg/mL ascorbic acid, and 10 mM β-glycerophosphate).
Cells were collected at each indicated time point for RNA extraction.
2.6. Real-time RT-PCR (RT-qPCR)
RNA extraction and real-time RT-PCR were performed as previously
described [9]. Brieﬂy, total RNAwas extractedwith Sepasol-RNA I Super
G (Nacalai Tesque, Japan) and an RNeasyMini Kit (Qiagen, USA) accord-
ing to the manufacturers' instructions. Total RNA was reverse tran-
scribed with a PrimeScript RT Master Mix (Takara Bio, Inc., Japan)
according to the manufacturer's instructions. Real-time PCR was per-
formed with Kapa SYBR Fast qPCR Kits (Kapa Biosystems, USA) and
the Thermal Cycler Dice Real-Time System (Takara Bio, Inc., Japan).
The Rplp0 gene served as an internal control. Speciﬁc primers for each
gene are listed below:
Rplp0: 5′-TTCCAGGCTTTGGGCATCA-3′ and 5′-ATGTTCAGCATGTTCA
GCAGTGTG-3′; Srebf1: 5′-TGGTTGTTGATGAGCTGGAG-3′ and 5′-
GGCTCTGGAACAGACACTG-3; Srebf2: 5′-TGCACCAGAGAGCATTTT
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TTCAACGC-3′ and 5′-CGCAAAAGTCCTGTGTGTTG-3′; Nfatc1: 5′-
GGGACCAACCGTATTTCCACAC-3′ and 5′-TCGGTAGCCAGCCAGGAA
TC-3′; Acp5: 5′-TTGCGACCATTGTTAGCCACATA-3′ and 5′-TCAGAT
CCATAGTGAAACCGCAAG-3′; Ctsk: 5′-ACCACTTGGGAGACATGACC-
3′ and 5′-ACCAACACTGCATGGTTCA-3′; LdlR: 5′-AATGGGGGCAAT
CGGAAAAC-3′ and 5′-TGGCACTGAAAATGGCTTCG-3′.
2.7. Western blotting
RAW264 cells were treated with ethanol (EtOH) or fatostatin
(10 μM, Merck Millipore, USA) for 24 h. Cells were washed with ice-
cold PBS and dissolved with RIPA buffer (50 mM Tris–HCl, pH 8.0,
150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS,
1 mMEDTA and protease inhibitors). Whole-cell extracts were separat-
ed by SDS-PAGE and transferred to polyvinylidene ﬂuoride (PVDF)
membranes. The membranes were blocked with 5% skim milk in
PBS with Tween-20 (PBST). Then, anti-Srebp2 antibody (4 μg/mL,
ab30682, Abcam, USA), anti-Srebp1 antibody (2 μg/mL, ab3259,
Abcam, USA) or anti-β-actin antibody (1 μg/mL, 2F3, Wako, Japan)
was bound overnight at 4 °C. After washing with PBST, HRP-
conjugated secondary antibody (1:1500, Dako) was bound for 1 h at
room temperature. Immunoreactive signals were detected with
Chemi-Lumi One Ultra (Nacalai Tesque, Japan) and ImageQuant LAS
4000 (GE Healthcare, USA).
2.8. RANKL-induced bone loss model, fatostatin treatment and serum
biochemistry
RANKL-induced bone loss was established as previously reported
[31,32]. Brieﬂy, GST-RANKL (2 mg/kg) or PBS was injected intraperito-
neally into 7-week-old femalemice. After 48 h, themicewere sacriﬁced
and the tibias were harvested for μCT and histological analysis. To inves-
tigate the effect of fatostatin on this bone loss model, fatostatin
(30 mg/kg, Merck Millipore, USA) was injected intraperitoneally 48 h
before the ﬁrst RANKL injection. Fatostatin injections were conducted
at 24-h intervals for 4 days before sacriﬁce. Five mice were used in
each group.
To examine the long-term effects of fatostatin, vehicle or fatostatin
(30 mg/kg) was injected intraperitoneally into 7-week-old female
mice twice a week for 3 weeks. After long-term treatment with
fatostatin, themicewere sacriﬁced, and the serawere collected formea-
surement of serum lipids and the tibias were harvested for μCT analysis.
Sevenmicewere used in each group. Serum lipids (total cholesterol, tri-
glycerides, HDL and LDL) were measured at a commercial laboratory
(Oriental Yeast Co., Ltd., Japan).
2.9. Micro-computed tomography (μCT) analysis
Micro-computed tomography (μCT) analysis was performed as pre-
viously reported [33,34]. Tibias were ﬁxed with 70% ethanol and sub-
jected to μCT analysis using a Scanco Medical μCT35 System (Scanco
Medical, Switzerland) with an isotropic voxel size of 6 μm for trabecular
analyses according to the manufacturer's instructions and the guide-
lines of the American Society for Bone and Mineral Research (ASBMR)
[35]. Two hundred slices of proximal tibial metaphysis starting at
0.6 mm from the end of the growth plate were scanned and analyzed.
Three-dimensional reconstructions were generated and analyzedFig. 1. Srebf2 positively regulated osteoclast differentiation in vitro. Relative mRNA expression l
sured by RT-qPCR (n=3 biological replicates). Bars representmeans± SD. C) The two left pane
control siRNA (N.C.) or siSrebf2. The number of TRAP-positivemultinucleated cells (TRAP+MNC
N.C. D) RAW264 cells were transfectedwith siRNA for either N.C. or Srebf2 for 36 h. RT-qPCR (n
Nfatc1, Acp5, CtsK and LdlR. Bars represent means ± SD.according to the manufacturer's instructions and the ASBMR guidelines
[35].
2.10. Bone histomorphometry
For TRAP staining, tibiaswereﬁxed in 70% ethanol for 3 days, and the
nondecalciﬁed bones were embedded inmethyl methacrylate. Longitu-
dinal 5-μmthick sectionswere cut on amicrotome (Leica RM2255, Leica
Microsystems, Germany) and subjected to TRAP staining using a TRAP/
ALP Stain kit (Wako, Japan) according to the manufacturer's protocol.
Histomorphometry of the secondary spongiosa was performed with
the OsteoMeasure analysis system (OsteoMetrics, USA) at 200-fold
magniﬁcation according to the ASBMR guidelines [36].
2.11. Statistical analysis
Statistical analyses were performed as previously described [9] with
Excel (Microsoft, USA) or SPSS (IBM, USA). Data were evaluated by a
two-tailed Student's t-test or by one-way analysis of variance
(ANOVA) followed by Bonferroni post hoc tests. For all graphs, data
are shown as means ± standard deviation (SD). Statistical signiﬁcance
is indicated as *, p b 0.05 and **, p b 0.01.
3. Results
3.1. Srebf2 positively regulated osteoclast differentiation in vitro
To clarify the functions of the Srebf2 gene in osteoclasts, we ﬁrst an-
alyzed changes of Srebf2 mRNA expression during primary osteoclast
differentiation. Srebf2mRNA was remarkably increasing during osteo-
clast differentiation, whereas the expression level of Srebf1mRNA was
not changed (Fig. 1A), suggesting that Srebf2 but not Srebf1 might
have a major role in osteoclast differentiation. To the contrary, Srebf1
mRNA increased and Srebf2mRNA decreased during osteoblast differ-
entiation (Fig. 1B). These results indicated that Srebf2might predomi-
nantly regulate osteoclast differentiation. We then investigated the
functions of Srebf2 in osteoclast differentiation using gene silencing.
Knockdown of Srebf2 using siRNA led to a signiﬁcant decrease in the
number of TRAP-positive multinucleated osteoclasts compared with
the control siRNA transfected cells (Fig. 1C). Gene expression analysis
showed that gene silencing of Srebf2 decreased the expression of osteo-
clast differentiation marker genes, including Fos, Acp5 and Ctsk as well
as LdlR, which is a target gene of SREBP2 (Fig. 1D). These results
suggested that Srebf2 might be a positive regulator of osteoclast
differentiation.
3.2. Fatostatin inhibited osteoclast differentiation in vitro
To reveal the physiological functions of Srebf2/SREBP2 in osteoclast
differentiation, we sought to analyze bone metabolism in SREBP2
knockout mice. However, systemic SREBP2 knockout mice showed em-
bryonic lethality [28], and SREBP2 ﬂoxed mice have not been available.
Therefore, we tried to abrogate the functions of SREBP2 through the
in vivo use of an inhibitor of SREBP2 activation. Fatostatin is a recently
described small organic molecule that inhibits the activation of SREBPs.
Fatostatin treatment was shown to improve hyperglycemia and exces-
sive accumulation of fat in the livers of ob/obmice [30]. Hence, we hy-
pothesized that fatostatin would impair osteoclast differentiation by
blocking of the activation of SREBP2.evels of Srebf1 and Srebf2 during A) osteoclast and B) osteoblast differentiation weremea-
ls show representative images of TRAP staining of RAW264 cells transfectedwith negative
s)was counted (n=4biological replicates). Bars representmeans±SD. **, p b 0.01 versus
= 3 biological replicates) was used to assess relativemRNA expression levels of Srebf2, Fos,
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SREBP2 in osteoclasts. RAW264 cells were treated with fatostatin for
24 h, and the levels ofmature SREBP2 proteinwere assessed byWestern
blotting. We observed that mature SREBP2 protein was decreased by
fatostatin treatment (Fig. 2A, lane 2) compared with vehicle treatment
(lane 1). In addition, it was increased by RANKL stimulation (lane
3) and RANKL-induced SREBP2 maturation was abrogated by fatostatin
treatment (lane 4), suggesting that fatostatin blocked the cleavage and
the activation of SREBP2 in osteoclasts. Meanwhile, mature SREBP1 pro-
tein was decreased by fatostatin treatment (Fig. S1, lane 2) compared
with vehicle treatment (lane 1). In addition, RANKL treatment de-
creased mature SREBP1 protein levels (lane 3), and RANKL-induced
SREBP1 maturation was unchanged by fatostatin (lane 4), suggesting
that fatostatin inhibited the cleavage of SREBP1 in macrophage-like
cells, while fatostatin did not affect the cleavage of SREBP1 in the pres-
ence of RANKL. Next, we investigated the effects of fatostatin on osteo-
clast differentiation. As fatostatin has cytotoxic effects on RAW264 cells
and BMMs at high concentration (15–20 μM), we examined the effects
of fatostatin on osteoclast differentiation at 10 μM (Fig. S2). Treatment
of RAW264 cells with fatostatin remarkably suppressed RANKL-
induced osteoclast differentiation and signiﬁcantly decreased the num-
ber of TRAP-positive multinucleated osteoclasts compared with vehicle
treated cells (Fig. 2B). To investigate the effects of fatostatin on osteo-
clastic gene expression, mRNA expression analyses during osteoclast
differentiation were performed. Consistent with a previous report
[37], osteoclast marker genes were upregulated by RANKL for 24 h
and theywere gradually decreased until 72 h. The expression of marker
genes upregulated by RANKL was not affected by fatostatin at the
early stage of osteoclast differentiation (Fig. 2C), whereas fatostatin
treatment signiﬁcantly reduced osteoclast marker gene expression
after 48 h (Fig. 2D and E). These data showed that fatostatin inhibited
in vitro osteoclast differentiation by hampering the activation of
SREBP2 and the subsequent transcriptional activation of osteoclastic
genes.
3.3. Fatostatin suppressed bone loss and osteoclast differentiation in a
RANKL-induced bone loss model
To supplement the in vitro observations above, we examined the
in vivo pharmacological effects of fatostatin on bone metabolism. First,
we investigated the effects of fatostatin on bone metabolism under
physiological conditions. Vehicle or fatostatinwas delivered intraperito-
neally into 7-week-old female mice for 3 weeks. After long-term treat-
ment with fatostatin, we evaluated its effects on cholesterol and bone
metabolism. While the serum levels of HDL were slightly reduced in
the fatostatin-treatedmice, other serum lipids and the bone parameters
in the fatostatin-treated mice were not changed compared to those in
the control mice (Fig. S3). These results suggested that fatostatin
might not affect bone and cholesterol metabolism under physiological
conditions. Therefore, we next examined the effects of fatostatin on
bone metabolism under pathological conditions. Towards that end, we
administered fatostatin to mice using a RANKL-induced bone loss
model. In this model, acute loss of trabecular bone is caused by in-
creased osteoclastic bone resorptionwithin two dayswithout alteration
of osteoblastic bone formation parameters [31]. Fatostatin, RANKL or ve-
hicles were injected intraperitoneally according to the experimental
schedule shown in Fig. 3A. Forty-eight hours after RANKL injection,
the mice were sacriﬁced and the tibiae were harvested. To evaluate
the effects of fatostatin on bone mass and its structure in RANKL-Fig. 2. Fatostatin inhibited osteoclast differentiation in vitro. A) Mature SREBP2 protein levels fr
ting. RAW264 cells were treated with vehicle or fatostatin (10 μM) with or without RANKL for
mature SREBP2 levels to actin controls. B) The number of TRAP-positive multinucleated cells
**, p b 0.01 versus vehicle control. Left panels show representative images of TRAP staining of
teoclast marker genes treated with vehicle or fatostatin for C) 24 h, D) 48 h and E) 72 h were minduced bone loss, we performed μCT analysis of the tibiae obtained
frommice thatwere treatedwith orwithout RANKL and fatostatin. Rep-
resentative 3D reconstructions of proximal tibial trabecular bone
showed that RANKL-induced bone loss was prevented by fatostatin
treatment (Fig. 3B). Analysis of the 3D parameters revealed that
fatostatin treatment signiﬁcantly rescued the RANKL-induced decrease
of trabecular BV/TV and Tb. N, and increased Tb. Sp. (Fig. 3C), whereas
fatostatin had no effect on cortical bone parameters that were not im-
paired by RANKL treatment (Fig. 3D). These results indicated that
fatostatin might prevent RANKL-induced trabecular bone loss.
To reveal how fatostatin rescued RANKL-induced bone loss and
whether fatostatin affected osteoclast differentiation in vivo, we per-
formed bone histomorphometric analyses using TRAP staining of the
sections of proximal tibial trabecular bones obtained from each group
(Fig. 4A). Bone histomorphometric analyses showed that osteoclast sur-
faces and the number of TRAP-positive osteoclasts per bone perimeter
were signiﬁcantly increased by RANKL treatment, and the elevation of
these osteoclastic parameters was completely blocked in fatostatin-
treated mice (Fig. 4B). These results suggested that fatostatin might in-
hibit osteoclast differentiation in vivo and prevent bone loss induced by
increased bone resorption, such as occurs in osteopenia.
4. Discussion
Transcriptional regulation of osteoclast differentiation involves sev-
eral transcription factors [38]. To gain further insights into the transcrip-
tional mechanisms underlying osteoclast differentiation, we previously
performed DNase-seq to identify open chromatin regions during osteo-
clast differentiation and succeeded in identifying several novel tran-
scription factors, including Srebf2 [9]. However, the physiological
functions of Srebf2/SREBP2 in osteoclasts have not been clear. In this
study,we demonstrated that SREBP2 appeared to positively regulate os-
teoclast differentiation in vivo as well as in vitro by using an inhibitor of
SREBPs, fatostatin.
SREBP2 is well known as a master regulator of cholesterol homeo-
stasis with positive transcriptional regulation of LDLR andHMG-CoA re-
ductase [28]. Recent studies reported that exogenous cholesterol is
important for osteoclast differentiation and survival. The absence of ex-
ogenous cholesterol, including LDL, impaired osteoclast formation, fu-
sion, morphology and survival [13]. LDLR knockout mice showed
increased bone mass with reduced osteoclast fusion and spreading
[39]. Moreover, it has been reported that simvastatin, one of the
cholesterol-lowering statins, inhibited osteoclast differentiation and re-
duced bone loss in a RANKL-induced bone loss model [32]. In our cur-
rent study, we showed that SREBP2 knockdown in osteoclasts led to
decreased expression of Ldlr mRNA. Therefore, one of the possible
mechanisms through which SREBP2 controls osteoclast differentiation
might be mediated through Ldlr gene expression and cholesterol
uptake.
In this study, we showed that SREBP2 knockdown reduced not only
LdlRmRNA but also FosmRNA. Therefore, SREBP2 might transcription-
ally control non-cholesterogenic genes to regulate osteoclast differenti-
ation. SREBP2 knockdown decreased FosmRNA levels. However, mRNA
levels of Nfatc1 (a target of Fos) were not changed (Fig. 1D). This result
indicated that Fos mRNA levels were decreased but Fos protein levels
were not changed at the time of analysis. In our SREBP2 knockdown
experiments, gene expression analysis was performed 36 h after
siRNA transfection. Therefore, we might observe primary changes of
gene expression induced by SREBP2 down-regulation. Moreover, theom osteoclasts treated with or without RANKL/fatostatin were measured byWestern blot-
24 h. Actin was used as a loading control. Right panel shows quantiﬁcation of normalized
(TRAP+ MNCs) was counted (n = 4 biological replicates). Bars represent means ± SD.
osteoclasts treated with vehicle or fatostatin. C–E) Relative mRNA expression levels of os-
easured by RT-qPCR (n = 3 biological replicates). Bars represent means ± SD.
2438 K. Inoue, Y. Imai / Biochimica et Biophysica Acta 1852 (2015) 2432–2441
Fig. 4. Fatostatin suppressed osteoclast differentiation in the RANKL-induced bone loss model. A) Representative images of TRAP staining of proximal tibial metaphyses in mice treated
with PBS, or GST-RANKL plus vehicle or GST-RANKL plus fatostatin. B) Bone histomorphometric analysis of proximal tibial metaphyses in mice of each group. Bars represent means ±
SD. n = 5/group, **, p b 0.01.
2439K. Inoue, Y. Imai / Biochimica et Biophysica Acta 1852 (2015) 2432–2441differences in the results of gene expression analyses from SREBP2
knockdown and fatostatin treatmentmight have been due to the differ-
ences in the time point of RNA isolation. To clarify the transcriptional
networks regulated by SREBP2 in osteoclasts, identiﬁcation of the target
genes of SREBP2 by genome-wide analyses might be needed. A recent
study succeeded in identifying SREBP2 target genes in mouse liver
with ChIP-seq analysis [40]. Hence, we might be able to identify
SREBP2 target genes in osteoclasts using ChIP-seq in combination with
RNA-seq during osteoclast differentiation. This approachmight provide
novel insights into transcriptional regulatory mechanisms underlying
osteoclast differentiation and functions.
In addition, we demonstrated that inhibition of SREBP2 activation
with fatostatin suppressed osteoclast differentiation both in vivo and
in vitro and maintained bone mass in a RANKL-induced bone loss
model. These results suggested that SREBP2 might be a positive regula-
tor of osteoclast differentiation and inhibitors of SREBP2 activation mayFig. 3. Fatostatin suppressed bone loss in a RANKL-induced bone loss model. A) Schematic rep
with vehicle or fatostatin. B) Representative reconstructed 3D μCT images of proximal tibia in
with fatostatin (RANKL + fatostatin). C) Quantitative μCT analysis of trabecular structure in m
Bars represent means ± SD. n = 5/group, *, p b 0.05 and **, p b 0.01.offer potential therapeutic treatments for osteoporosis or bone destruc-
tion in rheumatoid arthritis. In the RANKL-induced bone loss model, we
used fatostatin for short periods. Long-term treatment with fatostatin
reportedly led to reduced body weight and improved blood glucose
and hepatic fat accumulation in Ob/Obmice [30]. However, our results
showed that long-term treatment with fatostatin under physiological
conditions did not affect bone or cholesterol metabolism, suggesting
that fatostatin might be effective for bone and lipid metabolism under
pathological conditions. Whereas fatostatin treatment did not affect
cortical bone metabolism in our model (Fig. 3D), Srebf1mRNA was in-
creased during osteoblast differentiation (Fig. 1A). This result suggested
that fatostatin might affect osteoblast differentiation. The RANKL-
induced bone loss model, which lasts for just two days, is convenient
for rapid analysis of osteoclast differentiation in vivo. However, this
model may not be appropriate for evaluation of the effects of fatostatin
on osteoblast differentiation because bone histomorphometric analysesresentation of the experimental schedule for the RANKL-induced bone loss model treated
mice treated with PBS (control), GST-RANKL plus vehicle (RANKL) or GST-RANKL along
ice of each group. D) Quantitative μCT analysis of cortical structure in mice of each group.
2440 K. Inoue, Y. Imai / Biochimica et Biophysica Acta 1852 (2015) 2432–2441revealed osteoblastic bone formation parameterswere not changed [31]
and osteoblast differentiation processes need a longer period for assess-
ment. Therefore, it would be preferable to evaluate the effects of long-
term administration of fatostatin on bone and/or other tissues using
an ovariectomized mouse bone loss model.
Fatostatin was originally discovered as an adipogenesis-blocking
reagent [41]. However, fatostatin also has anti-tumor activity that im-
paired the proliferation of IGF-associated tumors, including hepatocel-
lular carcinoma (Hep-G2 cells) and prostate cancer (DU145 cells) [41].
In our study, fatostatin reduced TRAP-positive multinucleated osteo-
clasts and suppressed the expression of osteoclast genes, including
Fos, Nfatc1, CtsK and Acp5. These results suggested that fatostatin
might inhibit osteoclast differentiation, but it is also possible that
fatostatin may inhibit proliferation of osteoclast precursors.
Inhibition of SREBP2 activation with fatostatin revealed pathophysi-
ological functions of SREBP2 in osteoclast differentiation and bone me-
tabolism. However, we cannot rule out indirect effects of fatostatin on
bone metabolism mediated through other tissues or other types of
cells. Therefore, genetic mouse models lacking Srebf2/SREBP2 should
be examined to reveal the physiological functions of SREBP2 in osteo-
clasts. Because of the embryonic lethality in systemic SREBP2 null
mice, osteoclast speciﬁc SREBP2-deﬁcient mice should be generated
using Cre/loxP technology. SREBP2 ﬂoxed mice have not yet been re-
ported, but International Knockout Mouse Consortium groups are gen-
erating a conditional knockout resource [42]. Such a strain would be
very useful for the generation of conditional SREBP2-deﬁcient mice,
permitting the clariﬁcation of the exact physiological functions of
SREBP2. Towards that end, it is likely that macrophage/monocyte-
speciﬁc LyzM-Cre mice [43] or CD11b-Cre [44] or osteoclast progenitor
speciﬁc RANK-Cre mice [45] would be applicable. Analysis of bone phe-
notypes in macrophage/osteoclast-speciﬁc SREBP2-deﬁcient mice will
clarify the molecular basis of SREBP2 in osteoclast differentiation and
will provide novel insights into osteoclast biology.
In conclusion, our study demonstrated that SREBP2might be a novel
transcription factor regulating osteoclast differentiation both in vivo and
in vitro. In addition, this study revealed that transcription factors regu-
lating cell differentiation that are identiﬁed by integrative genome-
wide analyses (such as DNase-seq) have physiological functions and
might offer therapeutic targets. Even though further studies are needed
to elucidate the precisemolecular basis of SREBP2 functions in boneme-
tabolism, SREBP2-speciﬁc inhibitors might provide novel therapeutic
strategies for osteoporosis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.08.018.Acknowledgment
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